secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001104659-25-026708
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal
------------------------------------------------------------------------

- Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.
- Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.
- Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.
- Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.
- No assurance that Company will ultimately regain compliance and remain listed on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/0001104659-25-026708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925026708/tm259958d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-026708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer